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Introduction: In a previous study with 96 septic patients, we found that circulating platelets in 6-months surviving
septic patients showed higher activity and quantity of cytochrome c oxidase (COX) normalized by citrate synthase
(CS) activity at moment of severe sepsis diagnosis than non-surviving septic patients. The objective of this study
was to estimate whether COX specific activity during the first week predicts 1-month sepsis survival in a larger
cohort of patients.
Methods: Using a prospective, multicenter, observational study carried out in six Spanish intensive care units with
198 severe septic patients, we determined COX activity per proteins (COXact/Prot) in circulating platelets at day 1,
4 and 8 of the severe sepsis diagnosis. Endpoints were 1-month and 6-months mortality.
Results: Survivor patients (n = 130) showed higher COXact/Prot (P < 0.001) than non-survivors (n = 68) at day 1, 4
and 8 of severe sepsis diagnosis. More than a half of the 6-months survivor patients showed an increase in their
COXact/Prot from day 1 to 8. However, most of the 1-month non-survivors exhibited a decrease in their COXact/
Prot from day 1 to 8. Multiple logistic regression analyses showed that of platelet COXact/Prot > 0.30 mOD/min/mg
at day 1 (P = 0.002), 4 (P = 0.006) and 8 (P = 0.02) was associated independently with 1-month mortality. Area under
the curve of COXact/Prot at day 1, 4 and 8 to predict 30-day survival were 0.70 (95% CI = 0.63-0.76; P < 0.001),
0.71 (95% CI = 0.64-0.77; P < 0.001) and 0.71 (95% CI = 0.64-0.78; P < 0.001), respectively.
Conclusions: The new findings of our study, to our knowledge the largest series reporting data about
mitochondrial function during follow-up in septic patients, were that septic patients that survive 1-month
have a higher platelet cytochrome oxidase activity at moment of sepsis diagnosis and during the first week than
non-survivors, and that platelet cytochrome oxidase activity at moment of sepsis diagnosis and during the first
week could be used as biomarker to predict the clinical outcome in septic patients.Introduction
Severe sepsis is a fatal condition associated with organ fail-
ure [1]. This organ dysfunction is related to tissue hypoxia
due to cellular inability to use oxygen [2]. Most cellular
oxygen is consumed by cytochrome oxidase (COX) in the
electron transport chain (ETC) of the mitochondrial oxi-
dative phosphorylation system (OXPHOS). Thus, in a
previous study of 96 patients with severe sepsis, we found* Correspondence: lorentemartin@msn.com
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unless otherwise stated.that 6-month survivors had higher platelet COX activity
normalized by citrate synthase (CS) activity at the time of
diagnosis than non-survivors [3]. Because the determin-
ation of platelet COX activity to assess ETC is a rapid,
easy and not very invasive protocol, this parameter could
be used as a biomarker of sepsis mortality. Moreover,
patients with low COX activity could benefit from drugs
that improve ETC [3].
However, despite the inclusion of 96 individuals as the
largest series reported to date in which COX activity has
been determined, it is still a relatively small cohort of
patients. Moreover, although 6-month survival allows the
analysis of long-term outcomes, this period is not thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lated to the initial sepsis event would affect the results. In
addition, COX activity was only determined in platelets
obtained at the time of diagnosis and potential changes
over time were not evaluated. To address these problems,
we have now determined COX-specific activity in a larger
population of septic patients, analyzed 1-month survival
and obtained blood samples not only within the first 24
hours after the diagnosis of severe sepsis but also on days
4 and 8.Material and methods
Design and subjects
A prospective, multicenter, observational, study was carried
out in six Spanish ICUs. The study was approved by the
Institutional Ethical Review Boards of the six hospitals par-
ticipating in the study: Hospital Universitario de Canarias
(La Laguna. Santa Cruz de Tenerife. Spain), Hospital
Universitario Nuestra Señora de Candelaria (Santa Cruz
de Tenerife. Spain), Hospital Universitario Dr. Negrín
(Las Palmas de Gran Canaria. Spain), Hospital Clínico
Universitario de Valencia (Valencia. Spain), Hospital San
Jorge (Huesca. Spain) and Hospital Insular (Las Palmas
de Gran Canaria. Spain). Written informed consent
from the patients or from the family members was
obtained.
Inclusion criteria were the diagnosis of severe sepsis ac-
cording to the International Sepsis Definitions Conference
criteria [5]. Exclusion criteria were: age <18 years, preg-
nancy, lactation, platelet transfusion, HIV, white blood cell
count <1,000 cells/μl, solid or hematological tumor, or
immunosuppressive, steroid or radiation therapy.Variables recorded
The following variables were recorded for each pa-
tient: sex, age, diabetes mellitus, chronic obstructive
pulmonary disease (COPD), ischemic heart disease,
chronic renal failure (defined as glomerular filtration
rate (GFR) <60 ml/minute per 1.73 m2), site of infec-
tion, microorganism responsible, bloodstream infec-
tion, empiric antimicrobial treatment, septic shock,
pressure of arterial oxygen/fraction inspired of oxygen
(PaO2/FIO2), creatinine, bilirubin, leukocytes, lactic
acid, platelets, international normalized ratio (INR),
activated partial thromboplastin time (aPTT), acute
physiology and chronic health evaluation (APACHE)-II
score [6] and sepsis-related organ failure assessment
(SOFA) score [7].Endpoints
We assessed survival at 1 month and 6 months as the
endpoints.Biochemical determination in platelets
Blood samples were collected from patients on day 1, 4
and 8 of diagnosis of severe sepsis for the determination
of COX. Day 1 was considered as the first day that
severe sepsis was diagnosed (baseline values). Day 4 was
considered as the day after 72 hours had elapsed, and
day 8 as the day after 7 days had elapsed since the diag-
nosis of severe sepsis.
Platelets were obtained according to previously described
protocols [8]. We measured the COX activity (COXact)
by using Mitoprofile® Human Complex IV Activity and
Quantity from Mitosciences (Invitrogen) according to the
manufacturer’s instructions. This kit immunocaptures
complex IV and activity is determined colorimetrically by
following the oxidation of reduced cytochrome c as an ab-
sorbance decrease at 550 nm. Protein levels were assayed
following previously described protocols [9], and were
expressed in mg. A NovoStar MBG Labtech microplate
instrument was used for COXact and protein determina-
tions. COX activity corrected by proteins (COXact/Prot)
was expressed as milli-optical density per minute per mg
of proteins (mOD/min/mg) multiplied by 100.
Statistical analysis
Categorical variables are reported as frequencies and
percentages and continuous variables are reported as
medians and interquartile ranges. Comparisons of cat-
egorical variables between survivors and non-survivors
were carried out with the chi-square test. Normality as-
sumption was tested with the Komogorov-Smirnov test.
Comparisons of continuous variables between survivors
and non-survivors were carried out using the Wilcoxon-
Mann–Whitney test. We used the Kruskal-Wallis test to
compare levels of COXact/Prot between patients grouped
by survival lower than 1 month, between 1 and 6 months
and more than 6 month; post-hoc comparison of pairs
was carried out with the Mann-Whitney test.
Multiple logistic regression analysis was used to deter-
mine the independent contribution of platelet COXact/
Prot >0.30 mOD/min/mg, lactic acid and SOFA score at
day 1, 4 and 8 to the prediction of 1- and 6-month mortal-
ity. Odds ratios (ORs) and 95% confidence intervals were
calculated as measures of the association. Receiver ope-
rating characteristic (ROC) analyses were carried out to
determine the goodness-of-fit of the COXact/Prot at day 1,
4 and 8 to predict 1- and 6-month mortality. Analysis of
survival with the Kaplan-Meier method curve and compar-
isons by log-rank test were carried out using COXact/Prot
lower/higher than 0.30 mOD/min/mg at day 1, 4 and 8 as
the independent variable and survival at 1 and 6 months as
the dependent variable. A P-value less than 0.05 was
considered statistically significant. Statistical analyses were
performed with SPSS v. 17.0 (SPSS Inc., Chicago, IL, USA)
and Med Calc v. 10.1.3.0 (Mariakerke, Belgium).
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In a previous study of 96 sepsis patients, we found that
6-month survivors had a higher platelet COXact/CSact
ratio at the time of diagnosis than non-survivors [3].
This result suggested that OXPHOS function could be
used as a biormarker of sepsis mortality. As we found a
tight correlation between COXact/CSact and COXact/
Prot (Spearman rho = 0.77; P <0.001) in these patients,
to confirm the association between OXPHOS function
and sepsis survival and simplify clinical protocols, we
have now studied COXact/Prot in a larger number of
individuals (198 sepsis patients). We have observed that
COXact/Prot at the time of sepsis diagnosis was signifi-
cantly higher in 6-month survivors than in non-survivors
among patients with sepsis (Table 1).
Although 6-month survival allows the analysis of long-
term outcomes [4], confounder factors unrelated to the
initial sepsis event could affect the results. Therefore, we
have repeated these analyses for 1-month survival because
this is a more frequently used parameter in sepsis patients.
We found that 1-month survivors of sepsis (n = 130)
had lower lactic acid (P <0.001), INR (P = 0.03), aPTT
(P = 0.01), APACHE-II score (P <0.001) and SOFA
score (P <0.001), and higher platelet count (P = 0.01)
at the time of diagnosis of severe sepsis than non-survivors
(n = 68). There were no differences in the other recorded
variables between survivors and non-survivors of sepsis
(Table 2) except in COXact/Prot. Severely septic patients
who survived 1 month had significantly higher COXact/
Prot at the time of sepsis diagnosis than non-survivors
(Table 1). Of 130 patients who survived 1 month, 21 died
before 6 months and their COXact/Prot values were notTable 1 Platelet cytochrome c oxidase activity per proteins (C
non-survival at 1 and 6 months









Medians (25th, 75th percentiles) are indicated.significantly different from those of 109 patients who sur-
vived for longer than 6 months (Table 3).
In addition, we found that 1-month survivor patients
had statistically significantly higher COXact/Prot at days
4 and 8 than non-survivor ones (Table 1).
We found statistically significant differences compar-
ing the proportions of patients with increasing COXact/
Prot from days 1 to 8 between patients surviving longer
than 6-months, 1 to 6 months, and less than 1 month
(55.0% (60/109), 38.1% (8/21), 29.7% (11/37), respect-
ively; P = 0.02). Comparing pairs of groups, we found an
increased proportion of patients with increasing COX-
act/Prot from days 1 to 8 among patients surviving lon-
ger than 6 months compared with those surviving less
than 1 month (P = 0.01), and we did not find statistically
significant differences between the 6-month survival
group and the group that survived 1 month but not 6
months (P = 0.23), or between patients who survived
1-month but not 6 months and those who did not
survive 1 month (P = 0.57).
Supporting the relationship between COXact/Prot
or its evolution with sepsis mortality, COXact/Prot at
day 1 of 31 patients who did not survive a week (0.06
(0.05-0-18)) was significantly lower (P = 0.03) than
that of 37 patients that survived more than a week but less
than 1 month (0.14 (0.07-0.32)).
Multiple logistic regression analyses showed that of
platelet COXact/Proteins >0.30 mOD/min/mg at day
1 (P = 0.002), day 4 (P = 0.006) and day 8 (P = 0.02)
was associated independently with 1-month mortality,
controlling for lactic acid levels and SOFA score
(Table 4).OXact/Prot) in sepsis patients according to survival or
Survivors Non-survivors P-value
0.27 (0.11, 0.76) 0.13 (0.05, 0.37) <0.001
(n = 109) (n = 89)
0.29 (0.13, 0.92) 0.11 (0.05, 0.42) <0.001
(n = 109) (n = 71)
0.59 (0.13, 1.00) 0.09 (0.04, 0.37) <0.001
(n = 109) (n = 58)
0.28 (0.11, 0.61) 0.10 (0.05, 0.26) <0.001
(n = 130) (n = 68)
0.29 (0.11, 0.92) 0.07 (0.05, 0.24) <0.001
(n = 130) (n = 50)
0.51 (0.10, 1.00) 0.06 (0.04, 0.25) <0.001
(n = 130) (n = 37)
Table 2 Characteristics of 1-month survivors and non-survivors among patients with sepsis
Survivors (n = 130) Non-survivors (n = 68) P-value
Gender, male, n (%) 89 (68.5) 41 (60.3) 0.27
Age, years, median ( 25th, 75th percentile) 54 (44, 64) 61 (50, 72) 0.11
Diabetes mellitus, n (%) 33 (25.4) 24 (35.3) 0.19
COPD, n (%) 15 (11.5) 9 (13.2) 0.82
Ischemic heart disease, n (%) 13 (10.0) 7 (10.3) 0.99
Chronic renal failure, n (%) 6 (4.6) 7 (10.3) 0.14
Site of infection, n (%) 0.40
Respiratory 72 (55.4) 40 (58.8)
Abdominal 39 (30.0) 18 (26.5)
Neurological 2 (1.5) 1 (1.5)
Urinary 8 (6.2) 2 (2.9)
Skin 6 (4.6) 1 (1.5)
Endocarditis 3 (2.3) 5 (7.3)
Osteomyelitis 0 1 (1.5)
Microorganism responsible, n (%)
Unknown 68 (52.3) 35 (51.5) 0.99
Gram-positive 28 (21.5) 19 (27.9) 0.38
Gram-negative 32 (24.6) 14 (20.6) 0.60
Fungii 3 (2.3) 3 (4.4) 0.42
Anaerobe 1 (0.8) 1 (1.5) 0.99
Bloodstream infection, n (%) 20 (15.4) 11 (16.2) 0.99
Empiric antimicrobial treatment, n (%) 0.89
Unknown if adequate due to negative cultures 65 (50.0) 33 (48.5)
Unknown if adequate due to diagnosis by antigenuria 4 (3.1) 3 (4.4)
Adequate 55 (42.3) 30 (44.1)
Inadequate 6 (4.6) 2 (2.9)
Betalactamic more aminoglycoside, n (%) 26 (20.0) 16 (23.5) 0.59
Aminoglycoside, n (%) 36 (27.7) 18 (26.5) 0.99
Betalactamic more quinolone, n (%) 70 (53.8) 36 (52.9) 0.99
Septic shock, n (%) 109 (83.8) 62 (91.2) 0.19
PaO2/FIO2 ratio, median (25
th, 75th percentile) 159 (105, 260) 168 (109, 237) 0.58
Creatinine, mg/dl , median (25th, 75th percentile) 1.10 (0.80, 1.90) 1.60 (0.90, 2.65) 0.08
Bilirubin, mg/dl, median (25th, 75th percentile) 0.90 (0.40, 1.55) 0.88 (0.47, 2.54) 0.63
Leukocytes, cells/μl, median*103 (25th, 75th percentile) 14.0 (8.6, 21.5) 15.1 (6.4, 20.2) 0.84
Lactic acid, mmol/l, median (25th, 75th percentile) 1.80 (1.20, 3.50) 3.80 (1.55, 6.25) <0.001
Platelets, cells/μl, median*103 (25th, 75th percentile) 192 (112, 267) 124 (64, 196) 0.01
INR, median (25th, 75th percentile) 1.26 (1.10, 1.50) 1.42 (1.15, 1.68) 0.03
aPTT, seconds, median (25th, 75th percentile) 32 (28, 37) 38 (29, 45) 0.01
APACHE-II score, median (25th, 75th percentile) 18 (14, 23) 23 (17, 28) <0.001
SOFA score, median (25th, 75th percentile) 9 (7, 12) 11 (9, 14) 0.001
COPD, chronic obstructive pulmonary disease; PaO2/FIO2, pressure of arterial oxygen/fraction inspired oxygen; INR, international normalized ratio; aPTT, activated
partial thromboplastin time; APACHE, acute physiology and chronic health evaluation; SOFA, sepsis-related organ failure assessment.
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Table 3 Platelet cytochrome c oxidase activity per
proteins (COXact/Prot) of 6-month survivors, 1-month but
non-6-month survivors and 1-month non-survivors
Day 6MS 1MS/6MN-S 1MN-S P-value
Day 1 0.27 (0.11-0.76)* 0.46 (0.13-0.50)† 0.10 (0.05-0.26) <0.001
(n = 109) (n = 21) (n = 68)
Day 4 0.29 (0.13-0.92)* 0.25 (0.09-0.71)† 0.07 (0.05-0.24) <0.001
(n = 109) (n = 21) (n = 50)
Day 8 0.59 (0.13-1.00)* 0.15 (0.08-0.68) 0.06 (0.04-0.25) <0.001
(n = 109) (n = 21) (n = 37)
*P-values <0.001 for the comparison between patients who were 6-month
survivors (6MS) and 1-month non-survivors (1MN-S); †P-values <0.05 for the
comparison between patients who were 1-month but non-6-month survivors
(1MS/6MN-S) and 1MN-S. The remainder of the paired comparisons were not
statistically significant.
Figure 1 Receiver operation characteristic analyses using platelet
cytochrome c oxidase activity per protein (COXact/Prot) at 1, 4
and 8 days after admission as a predictor of mortality at 1 month
in septic patients.
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to predict 1-month survival were 0.70 (95% CI 0.63, 0.76;
P <0.001), 0.71 (95% CI 0.64, 0.77; P <0.001) and 0.71
(95% CI 0.64, 0.78; P <0.001), respectively (Figure 1).
Kaplan-Meier survival analysis showed that patients
with COXact/Prot higher than 0.30 mOD/min/mg of
proteins at day 1 (log-rank = 11.0; P < 0.001) (Figure 2), day
4 (log-rank = 11.0; P < 0.001), and day 8 (log-rank = 13.0;
P < 0.001) had a higher probability of survival at 1-month
than patients with lower COXact/Prot.
Discussion
Platelets contain small numbers of fully functional mito-
chondria. Their abundance in blood as well as the relative
ease to obtain them with minimally invasive protocols hasTable 4 Multiple logistic regression analyses to predict








mOD/min/mg at day 1
0.34 0.17, 0.67 0.002
Lactic acid at day 1 1.19 1.05, 1.34 0.004
SOFA score at day 1 1.07 0.98, 1.17 0.13
Second model
Platelet COXact/Prot >0.30
mOD/min/mg at day 4
0.30 0.13, 0.71 0.006
Lactic acid at day 4 1.49 1.06, 2.07 0.02
SOFA score at day 4 1.13 1.03, 1.24 0.01
Third model
Platelet COXact/Prot >0.30
mOD/min/mg at day 8
0.34 0.13, 0.87 0.02
Lactic acid at day 8 1.16 0.75, 1.80 0.51
SOFA score at day 8 1.16 1.06, 1.26 0.001
COXact/Prot, cytochrome c oxidase specific activity; SOFA, sepsis-related organ
failure assessment.made platelets an attractive source of human mitochon-
dria. Platelet OXPHOS function has frequently been used
to study OXPHOS dysfunction as a biomarker in human
disease [10]. COXact/Prot can be used as a surrogate of
OXPHOS function. Because COX subunits are lower inFigure 2 Cumulative proportion of survival septic patients at
1-month using platelet cytochrome c oxidase activity per
proteins (COXact/Prot) higher or lower than 0.30 mOD/min/mg
of proteins.
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ology associated with decreased COXact/Prot will be most
readily revealed in platelets [11]. Some commercial kits
are able to determine COXact/Prot using a microplate
reader, an instrument frequently found in the clinical
chemistry laboratories from most of the hospitals. There-
fore, to verify our previous observation that platelet
OXPHOS function can be used as a biomarker of sepsis
mortality [3] and simplify clinical protocols, we have now
studied the COXact/Prot in a larger number of sepsis
patients using a fast and easy test.
We have confirmed that platelet COXact/Prot at
the time of diagnosis of sepsis is significantly higher
in 1-month survivors than in non-survivors. It would be
possible that some individuals have a lower basal OXPHOS
capacity and, for them, the sepsis insult may represent an
unbearable stress. In fact, we have already observed that
there are OXPHOS differences between transmitochon-
drial cell lines with distinct mitochondrial DNA (mtDNA)
genetic backgrounds (haplogroups) obtained from normal
individuals [12] and that patients from mtDNA haplogroup
JT have a higher platelet OXPHOS function and 1-month
survival [13,14].
It has been reported that OXPHOS inhibition can affect
the platelet prothrombotic function [15,16]. However, on
the contrary, activation of coagulation frequently occurs
in sepsis [17]. Therefore, platelet OXPHOS dysfunction
observed in sepsis patients probably is not enough to alter
platelet function and increase mortality. However, as pre-
viously discussed, sepsis provokes mitochondrial dysfunc-
tion in different tissues from different species [3]. Thus,
the lower platelet COXact/Prot in non-surviving patients
probably mirrors a general situation in other tissues and
organs and this general lower OXPHOS function would
be one of the reasons for death.
It is possible that independently of their basal COXact/
Prot, non-surviving patients have an impaired response to
the septic insult. COXact/Prot changes along the time.
Thus, a higher percentage of 6-month survivors have
increased COXact/Prot along the first week compared to
patients who do not survive 1 month. An interesting as-
pect is that the patients who died after 1 month but within
6 months of the sepsis event had an initial COXact/Prot
similar to that of those who survived more than 6 months;
however, the percentage of patients with increased COX-
act/Prot along the first week was lower among patients
who survived 1 month but died within 6 months of the
sepsis compared to those who survived 6 months. If this
was the case, early determinations of platelet COXact/Prot
along the first week might help to predict the survival
probabilities and, for those patients with higher risk
of death, the administration of different compounds
that increase COXact/Prot may improve their survival
chances [18-20].Conclusions
Septic patients who survive 1 month have higher platelet
cytochrome oxidase-specific activity at the time of diag-
nosis than non survivors. A decrease in the platelet cyto-
chrome oxidase specific activity along the first week
after the sepsis diagnosis is a factor for poor prog-
nosis. Therefore, platelet cytochrome oxidase-specific
activity can be used as a biomarker of outcome in
septic patients.
Key messages
 Septic patients who survive 1 month have a
higher platelet cytochrome oxidase-specific activity
at the time of diagnosis than non survivors.
 A decrease in the platelet cytochrome
oxidase-specific activity along the first week
after the sepsis diagnosis a factor for poor prognosis.
 Platelet cytochrome oxidase-specific activity
can be used as a biomarker of outcome in
septic patients.
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